Search results for "Statins"

showing 10 items of 81 documents

In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1

1990

PharmacologyDrugDose-Response Relationship DrugBryostatin 1ChemistryInjections Subcutaneousmedia_common.quotation_subjectMice Inbred StrainsStimulationPharmacologyBryostatinsHematopoietic Stem CellsAntineoplastic Agents PhytogenicHematopoiesisLactonesMiceBryostatinsHaematopoiesisDose–response relationshipInbred strainIn vivoAnimalsFemaleMacrolidesmedia_commonPharmacological Research
researchProduct

The clinical relevance of low-density-lipoproteins size modulation by statins.

2006

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting en…

Simvastatinmedicine.medical_specialtyIndolesStatinmedicine.drug_classAtorvastatinFatty Acids MonounsaturatedInternal medicineAtorvastatinmedicineHumansPyrrolesPharmacology (medical)RosuvastatinParticle SizeRosuvastatin CalciumFluvastatinNational Cholesterol Education ProgramPharmacologySulfonamidesVascular diseasebusiness.industryAnticholesteremic Agentsstatins small dense LDL coronary heart disease atherosclerosis prevention therapyGeneral Medicinemedicine.diseaseFluorobenzenesLipoproteins LDLPyrimidinesEndocrinologyCardiovascular DiseasesHeptanoic AcidsSimvastatinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPravastatinmedicine.drugFluvastatin
researchProduct

Identification of a silicatein(-related) protease in the giant spicules of the deep-sea hexactinellid Monorhaphis chuni.

2008

SUMMARYSilicateins, members of the cathepsin L family, are enzymes that have been shown to be involved in the biosynthesis/condensation of biosilica in spicules from Demospongiae (phylum Porifera), e.g. Tethya aurantium and Suberites domuncula. The class Hexactinellida also forms spicules from this inorganic material. This class of sponges includes species that form the largest biogenic silica structures on earth. The giant basal spicules from the hexactinellids Monorhaphis chuni and Monorhaphis intermedia can reach lengths of up to 3 m and diameters of 10 mm. The giant spicules as well as the tauactines consist of a biosilica shell that surrounds the axial canal, which harbours the axial f…

SpiculePhysiologyOceans and SeasMolecular Sequence DataAquatic ScienceCysteine Proteinase InhibitorsCathepsin LDemospongeSponge spiculeAnimalsAmino Acid SequenceTethya aurantiumMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyBinding SitesbiologyHexactinellidAnimal StructuresAnatomybiology.organism_classificationCathepsinsCystatinsPoriferaSuberites domunculaMolecular WeightSpongeBiochemistryInsect ScienceMolecular Probesbiology.proteinAnimal Science and ZoologyProtein Processing Post-TranslationalThe Journal of experimental biology
researchProduct

Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study

2021

Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increas…

StatinMediterranean dietPhysiologymedicine.drug_classClinical Biochemistryphysical activityFibrateantiplatelet drugs030204 cardiovascular system & hematologyPharmacologyLower riskBiochemistryMetabolic equivalentArticlestatinscardiac glycosides03 medical and health sciences0302 clinical medicineMediterranean cookingMediterranean dietCuina mediterràniamedicine030212 general & internal medicinevitamin K epoxide reductase inhibitorsMolecular BiologyCardiac glycosideglucose-lowering drugsbusiness.industrylcsh:RM1-950mediterranean dietCell BiologyVitamin K antagonistPhysical fitnessCardiovascular agentslcsh:Therapeutics. Pharmacologyantihypertensive drugsantianginal drugsfibratesbusinessCohort studymedicine.drugCondició físicaMedicaments cardiovasculars
researchProduct

Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

2013

Abstract Among the various hypolipidemic drugs, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (also known as "statins") belong to a heterogeneous class of compounds, sharing an identical hypocholesterolemic effect that develops through direct inhibition of a rate-limiting step in endogenous cholesterol synthesis. Their mechanism of action entails competitive inhibition of HMG-CoA reductase. Several lines of evidence suggest that the pleiotropic effects of statins may also play a role in prevention of venous thrombosis, wherein hypercholesterolemic patients are characterized by enhanced thrombin generation, increased susceptibility to endothelial dysfunction and plate…

Statinmedicine.drug_classHMG-CoA; statins; thrombosisPharmacologyReductaseRisk AssessmentstatinsHyperlipoproteinemia Type IIHMG-CoARisk FactorsmedicineHumansPlateletEndothelial dysfunctionthrombosisHypolipidemic AgentsVenous Thrombosisbiologybusiness.industryC-reactive proteinHematologymedicine.diseaseThrombosisVenous thrombosisHMG-CoA reductasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Alteration of DNA topoisomerase II activity during infection of H9 cells by human immunodeficiency virus type 1 in vitro: a target for potential ther…

1990

Infection of H9 cells with human immunodeficiency virus type 1 (HIV-1) was found to decrease the phosphorylation of DNA topoisomerase II during the initial phase of infection. Simultaneously, with a later overshoot of phosphorylation and the subsequent activation of DNA topoisomerase II, the production of HIV-1 started. Applying three new protein kinase C inhibitors from the class of O-alkylglycerophospholipids we demonstrated that inhibition of protein kinase C-mediated phosphorylation of DNA topoisomerase II resulted in an inhibition of HIV-1 production. Based on the differential effect of the two protein kinase C activators, phorbol ester and bryostatin, we conclude that phosphorylation …

T-LymphocytesMitogen-activated protein kinase kinaseIn Vitro TechniquesMAP2K7Cell LineLactonesVirologyAnimalsPhosphorylationProtein kinase AProtein kinase CProtein Kinase CPharmacologybiologyCyclin-dependent kinase 2LysophosphatidylcholinesRats Inbred StrainsDNA topoisomerase II activityBryostatinsProtein kinase RMolecular biologyRatsDNA Topoisomerases Type Ibiology.proteinHIV-1Tetradecanoylphorbol AcetateCyclin-dependent kinase 9Electrophoresis Polyacrylamide GelMacrolidesAntiviral research
researchProduct

Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells

2015

Abstract Coevolution of ticks and the vertebrate immune system has led to the development of immunosuppressive molecules that prevent immediate response of skin-resident immune cells to quickly fend off the parasite. In this article, we demonstrate that the tick-derived immunosuppressor sialostatin L restrains IL-9 production by mast cells, whereas degranulation and IL-6 expression are both unaffected. In addition, the expression of IL-1β and IRF4 is strongly reduced in the presence of sialostatin L. Correspondingly, IRF4- or IL-1R–deficient mast cells exhibit a strong impairment in IL-9 production, demonstrating the importance of IRF4 and IL-1 in the regulation of the Il9 locus in mast cel…

Transcription GeneticCell DegranulationInterleukin-1betaImmunologyBiologyArticleCell DegranulationHost-Parasite InteractionsMiceImmune systemImmunityAnimalsImmunology and AllergyInterleukin 9Mast CellsPromoter Regions GeneticMice KnockoutRegulation of gene expressionMice Inbred BALB CBinding SitesInterleukin-6Interleukin-9DegranulationReceptors Interleukin-1CystatinsAsthmaImmunity InnateMice Inbred C57BLGene Expression RegulationInterferon Regulatory FactorsImmunologySignal transductionImmunosuppressive AgentsProtein BindingSignal TransductionInterferon regulatory factors
researchProduct

Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia

2020

Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.

bempedoic acidmedicine.medical_specialtyStatinmedicine.drug_classHyperlipidemiasFamilial hypercholesterolemia030204 cardiovascular system & hematologyLipid-lowering therapystatins03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansDicarboxylic AcidsIn patient030212 general & internal medicineHypolipidemic AgentsClinical Trials as Topiclipid-lowering therapyCholesterolbusiness.industryFatty Acidsnutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaselow-density lipoproteinchemistryDrug Therapy Combinationlipids (amino acids peptides and proteins)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsatherosclerosisCardiology and Cardiovascular MedicinebusinessBempedoic acidLipoproteinCoronary Artery Disease
researchProduct

Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinic…

2008

general practiceClinical Trials as TopicCardiovascular DiseasesStatins; primary prevention; elderly patients; general practiceIncidenceprimary preventionStatinsHumansHydroxymethylglutaryl-CoA Reductase Inhibitorselderly patientsUnited StatesAged
researchProduct

Treatment of primary hypercholesterolemia: comparison of the effectiveness of different statins

2000

hypercholesterolemiastatins LDL-C
researchProduct